Alterity Therapeutics Q1 FY26 Quarterly Cash Flow Report and Clinical Trial Updates

Alterity Therapeutics Limited released its Appendix 4C Quarterly Cash Flow Report for the quarter ending 30 September 2025 (Q1 FY26). The report highlights positive clinical trial results for ATH434, a treatment for Multiple System Atrophy (MSA). Key findings include strengthened efficacy signals at higher doses in the ATH434-201 double-blind trial and comparable treatment effects in the ATH434-202 open-label trial. An independent commercial assessment estimates a potential worldwide peak sales opportunity of USD $2.4 billion for ATH434. The company reported a cash balance of A$54.56M as of 30 September 2025. Alterity is actively engaging with the FDA to discuss nonclinical and manufacturing data required for Phase 3 trials, with an End-of-Phase 2 meeting expected in mid-2026. The company also completed a strategic placement, raising A$20M to advance its programs.